CSL SEQIRUS
LIVE

Serial Number

97542504

Owner

Seqirus UK Limited

Attorney

Nancy Sabarra

Filing Date

Aug 10, 2022

Add to watchlist:

No watchlists yet
View on USPTO

CSL SEQIRUS Trademark

Serial Number: 97542504 • Registration: 7877427

CSL SEQIRUS is a trademark filed by Seqirus UK Limited on August 10, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Seqirus UK Limited (138 trademarks)

Point, 29 Market Street

Entity Type: 98

Trademark Details

Filing Date

August 10, 2022

Registration Date

August 5, 2025

Published for Opposition

June 17, 2025

Goods & Services

Scientific and technological services, namely, scientific research and product development in the field of vaccines; scientific research, analysis, and testing in the field of medicine, pharmaceuticals, vaccines, and biotechnology; research and development services, namely, scientific, medical, pharmaceutical and blood products research and development services; industrial analysis of biotechnology and immunology processes for product development in the field of pharmaceuticals and vaccines; providing medical research and scientific research information about the results of clinical trials for pharmaceuticals and vaccines; providing medical research and scientific research information in the field of clinical trials; provision of testing facilities for pharmaceutical research; laboratory analysis and research in the fields of pharmaceuticals, vaccines, bacteriology, and chemistry; management of scientific research projects; providing technical research in the field of pharmaceutical studies through preparation of technical studies, technical reports, scientific reports; providing technical research in the field of pharmaceutical studies through preparation of scientific and medical research projects, preparation of statistics and reports relating to scientific and medical research; provision of scientific research services and facilities, provision of scientific research results, information and outcomes in the field of health and medicine; provision of pharmaceutical research information relating to the aforementioned services; pharmaceutical research advisory and consultancy services relating to the aforementioned services; dissemination of pharmaceutical research and medical research information relating to the aforementioned services over a global computer network; medical laboratory services through scientific testing and screening services, namely, medical laboratory testing of human blood plasma for safety and quality; medical laboratory services regarding human blood plasma

Education services including medical education services, namely, conducting classes, seminars, conferences, and workshops in the fields of pharmaceuticals, vaccines, biotechnology, biotherapy, immunology, rare diseases and blood conditions; health education, namely, providing classes in the field of health, vaccines, and immunology; consultancy services relating to education; provision of education services, namely, arranging and conducting of online conferences and symposia in the field of medical science via an online forum; provision of medical training and education courses in the field of health and medicine; publication of electronic educational materials; dissemination of printed and electronic educational material of others in the field of health and medicine; weblog services, namely, providing online non-downloadable blogs in the field of health and medicine; electronic publication of information on a wide range of topics, including online and over a global computer network, namely, electronic publishing of electronic publications featuring information on a wide range of topics

Medical services; medical information services; health care services; health care information services; patient support services, namely, providing an internet-based database of patient medical information where patients can inquire about medical issues and procedures related to vaccination and immunology; providing medical information concerning blood products; providing medical information concerning vaccines, anti-venoms and immunohaematology products being diagnostic reagents; patient support services, namely, providing patient medical information where patients can enquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community via an Internet-based database

Pharmaceutical preparations and substances for the treatment and prevention of influenza, respiratory disease and disorders, infectious diseases and disorders, cardiovascular diseases and disorders, stroke, and heart failure; pharmaceutical preparations and substances, namely, anti-virals and antibiotics; vaccines; blood products, namely, blood for medical purposes, blood plasma and cord blood for medical purposes; serums, namely, anti-venoms; medicated serums for the treatment of blood disorders and bleeding disorders; antibodies for use in the treatment of infectious diseases, cancer and autoimmune diseases; monoclonal and polyclonal antibodies for medical purposes; therapeutic monoclonal and polyclonal antibodies and antibodies for use in the treatment of infectious diseases; influenza vaccines; adjuvants for medical purposes and antigens being protein arrays for medical purposes; pharmaceutical preparations and substances for the treatment and prevention of blood or bleeding disorders; blood products, namely, blood plasma, reagent blood cells for medical use; products derived from blood and products derived from recombinant DNA technology, namely, blood substitutes being immunoglobulins, human albumin, blood clotting factors, plasma volume expanders, blood proteins for therapeutic human use; test kits, namely, invitro diagnostic reagent test kits comprised of medical diagnostic reagents for use in detecting cell mediated immune response; pharmaceutical preparations and substances, namely, RhD reagents for medical use for the detection of specific antigens and in blood typing; pharmaceutical preparations, namely, reagent red blood cells for medical purposes used to detect antibodies or IgG subtypes; pharmaceutical preparations, namely, monoclonal and polyclonal antibodies for pharmaceutical use; pharmaceutical preparations, namely, reagents for medical and clinical use for the typing and detection of specific blood cells, and the detection of relevant compliment components and immunoglobulin subtypes; diagnostic agents for medical purposes

Chemical and biological reagents for scientific purposes, research purposes, and non-medical purposes; cell culture reagents and media for scientific and research use; laboratory and scientific test kits for laboratory or research use, namely, reagent kits comprising generic DNA circle, DNA primers, polymerase and buffers for use in biotechnology fields; chemical preparations for scientific and industrial purposes; diagnostic and testing agents, namely, diagnostic reagents and diagnostic testing preparations for scientific and research use; chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for antibody screening, blood grouping, and for the typing and detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes all for non-medical purposes; chemical test kits for the detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant complement compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for industrial use for anti-body screening, blood grouping, and the typing and detection of specific blood cells

Filing History

CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 20, 2025 APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 17, 2025 APRE
TEAS SECTION 7 REQUEST RECEIVED
Aug 27, 2025 ES7R
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 5, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 5, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 17, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 17, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 11, 2025 NONP
ATTORNEY REVIEW COMPLETED
May 29, 2025 ATRV
CASE RETURNED TO EXAMINATION
May 27, 2025 OTHE
NOTICE OF ALLOWANCE CANCELLED
May 27, 2025 IUCN
JURISDICTION RESTORED TO EXAMINING ATTORNEY
May 23, 2025 JURT
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
May 23, 2025 PCBG
ASSIGNED TO PETITION STAFF
May 19, 2025 APET
TEAS PETITION TO AMEND BASIS RECEIVED
Apr 16, 2025 TPAD
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 25, 2025 EXRA
SOU EXTENSION 2 GRANTED
Mar 24, 2025 EX2G
SOU EXTENSION 2 FILED
Mar 24, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 24, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 19, 2024 EXRA
SOU EXTENSION 1 GRANTED
Sep 19, 2024 EX1G
SOU EXTENSION 1 FILED
Sep 19, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 19, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 26, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 30, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 30, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 10, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 28, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 28, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 28, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 28, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 28, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 6, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 5, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 5, 2023 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Aug 15, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Aug 15, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 5, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 5, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 5, 2023 CNRT
ASSIGNED TO EXAMINER
May 30, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 30, 2022 NWOS
NEW APPLICATION ENTERED
Aug 13, 2022 NWAP